R

Roche

Global pharmaceuticals and diagnostics company

Senior Regulatory Specialist

Full-TimeUpdated on 10/14/2026
No salary listed
Junior
Bachelor's
Beijing, China
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A bachelor’s degree or above in medicine, bioengineering, clinical medicine, biochemistry, or pharmacy, or a relevant background in one of these fields.
  • Expertise in NMPA registration regulations and policies.
  • Fluent English in listening, speaking, reading, and writing.
  • Computer skills, including operation of MS Office.
  • At least two years of experience in medical regulatory affairs, focused on testing centers and clinical trials, and familiarity with NMPA standards and guidelines.
  • Ability to work under pressure and work independently with initiative.
  • Interpersonal communication, social interaction, and collaboration skills.
  • Ability to innovate and work independently.
  • Ability to challenge and ask questions, with negotiation awareness and skills.
  • Demonstrate Roche values of Integrity, Courage, and Passion; follow Roche Operating Principles; and possess the core skillsets required for the role.
Responsibilities
  • Prepare registration dossiers for submission to NMPA and obtain approval in line with the registration plan.
  • Ensure registration dossiers are accurate and truthful, maintain submitted and approved dossiers in related IT systems, SharePoint, and V drive, and notify stakeholders according to company SOP requirements.
  • Complete related payment procedures in systems on time and place orders for free-of-charge quality-control testing.
  • Participate in discussions and verification of national standards, panel verifications, and national or industrial standard discussions and verifications; guide and influence standards formulation.
  • Work with the global team to draft PTRs and complete type testing on time when needed.
  • Participate in regulation and guidance discussions and provide feedback to authorities aligned with Roche Regulatory Strategy; guide and influence guideline formulation.
  • Provide regulatory support to internal departments as needed as a member of RD.
  • Handle daily work proactively, keep records, maintain clear filing and document management, and update information on time according to requirements.
  • Work productively in multifunctional teams, proactively resolve issues, build effective networks, and maintain efficient cross-functional collaboration.
  • Identify and assess regulations and related changes, and contribute ideas to key project registration strategies.
  • Conduct risk assessments, determine risk levels, anticipate regulatory risks throughout the product-line lifecycle, and develop mitigation plans in advance.
  • Develop registration strategies and propose innovative strategies using appropriate regulations and resources to accelerate product launches.
  • Manage stakeholder expectations from business-area perspectives and facilitate cross-functional project completion while meeting timelines, budgets, and compliance requirements.
  • Complete other projects or tasks assigned by the line manager.
  • Conduct business in full compliance with Roche Secure, Roche Behavior in Business, Roche Competition Law Interactive Dialogues, and Roche Safety, Security, Health and Environmental Protection requirements.
  • Understand and fulfill the line manager’s SHE tasks and duties as defined in the SHE handbook.
  • Fill registration dossiers and obtain approvals according to the registration plan while complying with regulations and SOPs.
  • Maintain registration and approved dossiers according to company requirements, and cross-check registration dossiers for accuracy and truthfulness.
  • Establish and maintain relationships with NMPA testing centers and obtain product QC testing reports according to the registration forecast plan.
  • Work closely with CO and CCOE teams to provide timely regulatory support.
  • Cooperate with other departments and maintain relationships with key contacts; recommend valuable suggestions to the company.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.

PR Newswire
Sep 30th, 2026
Roche launches newborn screening test for SMA, SCID and sickle cell disease

Roche has launched a newborn screening test that simultaneously detects three severe genetic conditions: Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease. TIB MOLBIOL, a Roche subsidiary, developed the LightMix Newborn TREC/SMN1/HBB kit for use in countries accepting the CE mark. The test enables early detection before symptoms appear, allowing clinicians to initiate life-changing treatments sooner. Early intervention can prevent severe nerve damage in SMA, enable lifesaving bone marrow transplants for SCID, and drastically lower infant mortality in SCD through preventive measures. The IVDR-approved test provides a ready-to-use solution that integrates into existing laboratory workflows. It runs on established LightCycler systems, making it accessible for private and academic hospital laboratories across Europe.

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.

World Today News
Sep 8th, 2026
Tempus AI raises $600M to scale AI-enhanced liquid biopsy platform for cancer recurrence detection

Tempus AI has raised $600 million in Series C funding to scale its machine learning platform for cancer recurrence detection through liquid biopsies. The investment was led by SoftBank Vision Fund 2, with participation from Roche and Merck. Phase II trial data showed the AI-enhanced liquid biopsy analysis reduced false-negative results by 37% compared to conventional methods. The platform uses deep learning algorithms trained on over 12,000 genomic profiles to identify circulating tumour DNA fragments shed by residual cancer cells. A 2025 Nature Medicine study reported the system achieved 92% specificity in detecting minimal residual disease across breast, lung, and colorectal cancers. According to SEC filings, 45% of funds will support FDA pre-market approval trials, whilst 30% will fund global expansion into EU and APAC markets.